Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma

Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

(2016) Anne C. Knol et al.   EXPERIMENTAL DERMATOLOGY

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients

(2016) C. M. Nijenhuis et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

(2016) Max Schreuer et al.   Journal of Translational Medicine

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients

(2016) Alicja Puszkiel et al.   PHARMACOLOGICAL RESEARCH

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations

(2016) Eleonora Zonta et al.   PLoS One

Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’ by Funck-Brentano et al.

(2015) L. Goldwirt et al.   ANNALS OF ONCOLOGY

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance

(2015) E. Funck-Brentano et al.   ANNALS OF ONCOLOGY

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

(2015) Mohammad Atefi et al.   Molecular Cancer

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

(2015) N. Kramkimel et al.   Targeted Oncology

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

(2015) Simon Chang-Hao Tsao et al.   Scientific Reports

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

(2014) M S Carlino et al.   BRITISH JOURNAL OF CANCER

Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

(2014) M. F. Sanmamed et al.   CLINICAL CHEMISTRY

Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

(2013) V. Taly et al.   CLINICAL CHEMISTRY

An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients

(2013) Yi Zhen et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Resistance to RAF Inhibitors Revisited

(2013) Edward Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab

(2013) Mark R. Gray et al.   RADIOLOGY

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number

(2011) Benjamin J. Hindson et al.   ANALYTICAL CHEMISTRY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of multiple serum markers in advanced melanoma

(2011) Angel Díaz-Lagares et al.   TUMOR BIOLOGY